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Summary This study evaluates the degree and relevance of persisting ototoxicity after cisplatin-based standard-dose chemotherapy for
testicular cancer, with emphasis on identification of potential factors for an increased risk of this late sequel. Hearing thresholds of 86 patients
with a median age of 31 years (range 21-53 years) and a median follow-up time of 58 months (range 15-159 months) were assessed by
conventional pure-tone audiometry. Interviews were conducted evaluating the patients' history with special regard to audiological riskfactors,
as well as circumstances of ototoxic symptoms. Details concerning treatment and patient variables were extracted retrospectively from the
patients' charts. An additional screening programme assessed current body functions, blood parameters and other late toxicities.
Symptomatic ototoxicity persisted in 20% of patients (59% tinnitus, 18% hearing loss, 23% both), while 10% had experienced completely
reversible ototoxic symptoms for a duration of 1-18 months after treatment. Symptoms were bilateral in 81% of patients. Hearing thresholds
were compatible with cisplatin-induced hearing loss in 42% of audiograms performed. Subjective (history) and objective (audiogram) findings
were not always consistent. The following statistically significant risk factors forototoxicity were established: high cumulative dose ofcisplatin
(P< 0.0001); history of noise exposure (P = 0.006). Additionally, high doses of vincristine (P = 0.001) seemed to result in reversible ototoxic
symptoms. No other independent risk factors were identified. In conclusion, persisting ototoxicity represents a clinical sequel for
approximately 20% of testicular cancer patients treated at standard dose but may affect more than 50% of patients receiving cumulative
doses of cisplatin > 400 mg m-2. Previous noise exposure may also result in a threefold increased risk forcisplatin ototoxicity. Future studies
should use these riskfactors as important stratification criteria fortrials aiming atthe evaluation and prevention ofcisplatin-induced ototoxicity.
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The ototoxic potential ofthe chemotherapeutic agent cisplatin was
recognized 2 decades ago (Piel et al, 1974). Despite the wide-
spread use of cisplatin in standard treatment protocols for testic-
ular, ovarian, head and neck, lung and other types ofcancers, data
on the frequencies of ototoxicity are not consistent, and risk
factors have not been clearly identified so far. The measurement of
the auditory function is limited because ofthe different diagnostic
methods used for objective assessment and the subjective percep-
tion of symptoms; patients' characteristics, such as age or noise
exposure, may additionally influence the hearing ability and
different definitions of 'normal' and 'abnormal' hearing thresh-
olds may also cause further discrepancies in reported results.
In the current study the auditory function was evaluated in a
homogeneous group of young men receiving cisplatin-based
combination chemotherapy for testicular cancer. Because of the
excellent long-term prognosis of patients with this type of solid
tumour (Bokemeyer, 1997; Bosl and Motzer, 1997), it was
possible to study the subjective and objective quality-of-hearing
impairment in an almost healthy patient cohort with emphasis
on long-term ototoxicity after a minimum follow-up period of
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15 months afterchemotherapy. Risk factors that could increase the
likelihood for ototoxicity were also analysed and discussed in
relation to the available literature.
MATERIALS AND METHODS
Patients
In this study, 182 patients treated for testicular cancer between
1976 and 1987 and followed through the oncological outpatients
clinic at Hannover University Medical School were invited to be
interviewed and examined concerning the detection of possible
late toxicities after chemotherapy. The evaluation of ototoxicity
was part of an extensive screening programme concerned with
identifying prevalence, relevance and risk factors for different
organ toxicities, such as neurotoxicity, vascular toxicity, gonadal
toxicity and other chemotherapy-induced alterations of body
functions (Bokemeyer et al, 1996). Only patients who had been in
complete remission for at least 12 months at the time ofexamina-
tion were included in the analysis. Ninety consecutive patients
during a 1-year period participated in the clinical examination,
blood tests and a personal interview. All patients were inter-
viewed for a detailed history of previous auditory symptoms and
potential risk factors, such as head injuries, ear infections,
previous noise exposure and family history of hearing impair-
ment. Emphasis was placed on the time of occurrence of symp-
toms in relation to chemotherapy, on the subjective impact of
ototoxic symptoms on the well-being and on the potential
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reversibility of symptoms. The data on tumour stage, previous
laboratory values and individual treatment variables were
extracted from the patients' charts. Only the data of the 86
patients who underwent pure-tone audiometry will be presented
in the following. The median age of the patients at the time of
chemotherapy was 26 years (range 19-50years) and at the time of
study 31 years (range 21-53 years). The median duration of
follow-up was 58 months (range 15-159 months).
Methods
To assess clinically relevant hearing sensitivity, pure-tone audiom-
etry was performed in a sound-treated acoustic chamber using a
Philips HP 8741/40 audiometer. Air and bone conduction thresh-
olds were determined at 0.5, 1, 2, 3, 4, 6 and 8 kHz, according to
the guidelines used at the Department for Otorhinolaryngology at
the Hannover University Medical School (Lehnhardt, 1978). We
defined the extent ofthreshold reduction necessary to be classified
as 'significant' hearing loss as at least 10 dB at two or more
consecutive frequencies or at least 20 dB at one isolated frequency
in air conduction. Results were compared with those of bone
conduction to rule out air-bone gaps implying conductive involve-
ment. A 'potentially' cisplatin-induced hearing loss was assumed
if a bilateral, significant sensorineural hearing loss increased
towards higher frequencies tested. However, audiometric findings
were only classified as chemotherapy-induced ototoxicity ifeither
the patients' current or previous symptoms were in relation to the
chemotherapy and compatible with the hearing loss or if normal
prechemotherapy audiograms were available.
Statistical analyses
Statistical analyses were performed using SPSS for Windows 6.0
software. Differences between means ormedians ofvariables were
tested according to their distribution andclassification ofmeasure-
ment scale. Pearson's chi-squared test was applied to categoric
variables. Analyses were repeated in stratified subgroups when-
ever possible to minimize confounding; additionally, logistic
regression analyses were used to estimate the prediction values
when testing multiple variables. All tests were two-tailed and
significance was accepted at the P < 0.05 level.
RESULTS
Subjective symptoms
Seventeen (20%) of the 86 patients complained of persisting
ototoxic symptoms possibly related to the chemotherapy. Tinnitus
was experienced by ten (12%) patients, hearing loss by three (3%)
patients and four (5%) patients were affected by both symptoms.
None ofthe patients had experienced vertigo as a sign of damage
of the vestibular organ. Not all of the patients showing clinical
ototoxicity had been free of symptoms before the chemotherapy:
3 (18%) of the 17 symptomatic patients stated an abrupt deterio-
ration of already prechemotherapeutic impaired hearing at the
time of chemotherapy. The remaining 14 (72%) patients had not
experienced any auditory dysfunction until chemotherapy. The
ototoxic symptoms were classified as 'very disturbing' by three
(18%) patients, 'moderately annoying' by seven (41%) and 'only
slightly annoying' by seven (41%) patients. For4 (24%) ofthe 17
patients, the intensity of the symptoms had decreased (three
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Figure 1 Average hearing loss (left ear) in the audiograms of 36 testicular
cancer patients compatible with symptomatic or asymptomatic ototoxicity
after cisplatin-based chemotherapy. Hearing sensitivity was tested by pure-
tone audiometry (air conduction). Boxes, 25-75 percentiles with median;
brackets, ranges; reference line (--- -) at 0 dB, normal hearing thresholds
tinnitus, one hearing loss), while symptoms for the remaining 13
(76%) patients had persisted unchanged (seven tinnitus, two
hearing loss, four both).
Eighteenofthe 86patients (21%) reportedprevious hearingprob-
lems or a history of chronic noise exposure before chemotherapy.
Nine (10%) patients hadexperienced completely reversible ototoxic
symptoms (seven tinnitus, two hearing loss) that had started during
or shortly afterthe chemotherapy andhad subsided afteramedian of
6 months (range 1-18 months). None of these nine patients had a
history of pre-existing auditory symptoms. The symptomatic
patients had experienced hearing loss always bilaterally, while
tinnitus was lateralized to only one ear in 5 (24%) of 21 patients
(three left, two right ear). Fifty-five (64%) of the patients had not
experienced any ototoxic symptoms; the remaining five (6%)
patients gave histories that were notcompletely reliable.
Audiometric findings
'Significant' hearing loss was observed in 57 (66%) of all 86
audiograms - 36 (42%) of which seemed compatible with
chemotherapy-related threshold alterations (increasing decline of
the hearing thresholds towards higherfrequencies, see Figure 1 for
details). The loss of hearing sensitivity was not always symmet-
rical in both ears, yet bilateral in the majority of cases. The other
21 (24%) audiograms showed abnormal hearing thresholds that
would be untypical for pharmacogenic damage, and therefore
were classified to be of other origin (unilateral deafness, C4-dips
typical for chronic noise exposition, etc.). Normal audiograms
were seen in 29 (34%) patients.
Correlation between subjective and objective findings
When comparing the results of the audiometric examination with
the histories of symptomatic ototoxicity obtained during the inter-
views, findings were not consistent. We observed both directions
of discrepancy: annoying symptoms with only slightly abnormal
audiometric findings, as well as a history ofcomplete reversibility
ofototoxic symptoms while the audiogram showed major hearing
impairment with only gradual improvement over time. Taking
both the subjective history and the audiometric findings into
consideration, 45 patients could be clearly classified, as they
British Journal ofCancer(1998) 77(8), 1355-1362
-1M i --
0 CancerResearch Campaign 1998Cisplatin-associated ototoxicity in testicularcancer 1357
U,
c
co CL
100
90
80-
70- 63%
60
50 44%
40
30 24% 25%
20
10% 6% 8%- 10 0% _now 2_ 4 6 n 61-1
85200 (n=16) 201-400 (n=38) 401-600 (n=l16) 601-1300 (n=l16)
Cumulative cisplatin dose (mg m-2)
Figure 2 Patients with persisting ototoxic symptoms or abnormal
audiometric findings in relation to the cumulative dose of cisplatin. D,
Persisting symptoms; E, audiogram compatible with ototoxicity. n, number
neither showed 'untypical' (probably not chemotherapy-related)
hearing impairment in the audiogram, nor gave histories of symp-
toms that seemed incompatible with the audiometric findings:
* 23 (51%) of45 patients with normal hearing thresholds and no
history of symptoms;
* 6 (13%) of45 patients with normal hearing thresholds and a
history oftransient, completely reversible symptoms;
* 16 (36%) of45 patients with 'typical' ototoxic hearing impair-
ment (see Materials and methods) and a history oftinnitus
and/or clinically apparent hearing loss (time of occurrence in
relation to chemotherapy).
The remaining 41 patients were not evaluable for a 'typical
picture' of therapy-related ototoxicity. Therefore, preliminary
statistical analyses were performed for the 45 'clearly classifiable'
patients and then confirmed for the whole cohort ofall 86 patients.
Risk factors for ototoxicity
The cumulative dose of cisplatin (DDP) was a highly significant
predictor for ototoxicity (P < 0.0001). The mean cumulative doses
were 297 mg m-2, 337 mg m-2 and 678 mg m-2 in the groups of
patients with no, transient and persisting ototoxicity respectively.
Persisting ototoxic symptoms (disturbing hearing loss and/or
annoying tinnitus) were present in 10 (63%) of 16 patients that had
received a cumulative dose of > 600 mg m-2 DDP, regardless
whether high or low single doses of DDP were applied. All 16
(100%) patients showed abnormal (i.e. 'possibly cisplatin-
induced') audiograms. The relationship of the cumulative DDP
dose and ototoxic symptoms, as well as the prevalences of
possibly chemotherapy-related threshold alterations, are presented
in Figure 2. Transient (four patients) or persisting (seven patients)
symptomatic ototoxicity was reported by 11 (61%) of 18 patients
that had received high single doses of DDP (35-50 mg m-2),
regardless of the cumulative dose; 4 (22%) of the 18 audiograms
were without 'possibly cisplatin-induced' threshold changes.
Although higher doses of DDP were associated with an
increased use of the diuretic furosemide during therapy, this
ototoxic agent could not be identified as an independent risk factor
for ototoxicity after chemotherapy.
Every patient who had received > 6 mg m-2 ofvincristine (Vcr)
in combination with any cumulative DDP dose stated transient or
persisting ototoxic symptoms; a tendency towards reversibility
was seen in those patients with low cumulative DDP doses
Table 1 Symptomatic ototoxicity in relation to the applied chemotherapy
regimens
Number Ototoxic symptoms
of patients
Persisting Transient None
All patients 86 17 (20)a 9 (10) 55 (64)
PVB 27 2 (7) 3 (11) 20 (74)
PEB 15 1 (7) 2 (13) 11 (73)
PEBVcr 10 1 (10) 4 (40) 5 (50)
P(high-dose)EB 10 7 (70) 0 (0) 3 (30)
PVB/PEb 5 5 (100) 0 (0) 0 (0)
Other 19 1 (5) 0 (0) 16 (84)
aNumbers in parentheses are percentages. bincludes salvage therapy.
P, cisplatin; V, vinblastine; B, bleomycin; E, etoposide; Vcr, vincristine.
(< 400 mg m-2). The correlation ofthe cumulative dose ofVcr and
ototoxicity was statistically significant (P = 0.001). The use and
the doses of bleomycin, etoposide, vinblastine and ifosfamide
were not independently associated with ototoxicity. The
frequencies of ototoxic symptoms in relation to the different
chemotherapy regimens are presented in Table 1.
Four patients with persistent ototoxic symptoms who had
received neither high DDP doses nor Vcr had pre-existing noise
exposure or hearing impairment as the only risk factors for the
development of ototoxicity. A history of noise exposure was
independently correlated to both persisting subjective symptoms
(P = 0.006) and audiographically verified ototoxic hearing impair-
ment (P = 0.04). Seven of 15 (47%) patients with previous noise
exposure compared with 10 of66 (15%) patients without ahistory
of noise exposure complained about ototoxic symptoms, resulting
in a 3.1-fold increased relative risk for ototoxicity in patients with
a history of noise exposure. Patients with or without a history of
noise exposure did not differ with respect to age, DDP orVcrdose.
Previous noise exposure did not seem to influence the incidence of
transient symptoms.
Abnormally low serum phosphate concentrations were seen in
more patients with ototoxicity than without. When controlling for
noise exposure and DDP dose, this association was statistically
significant in the logistic regressions analysis (P = 0.04). Serum
creatinine levels before chemotherapy in patients with persisting
ototoxicity showed higher levels (92 gmol 1-') than in patients
without (83 ,umol 1-') (P = 0.04). No other patients' or therapy
characteristics were identified as significant risk factors for oto-
toxicity: the analyses included age, smoking habits, anti-emetic
steroids, magnesium and/or potassium supplementation during
therapy, current serum magnesium, creatinine and calcium levels;
furthermore, serum albumin concentration before, during and after
chemotherapy.
DISCUSSION
Ototoxicity as a side-effect of cisplatin chemotherapy has been
recognized for more than 20 years (Piel et al, 1974). Despite the
clinical relevance of impaired hearing and the widespread use of
cisplatin for the treatment of solid tumours, only few systematic
studies have investigated the long-term impact, the prognosis and
the predictive factors for ototoxic damage. Table 2 summarizes the
literature on clinical studies of ototoxicity in cisplatin-treated
patients with testicular cancer.
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The cellular equivalent for cisplatin-related ototoxicity seems to
be the loss of the outer hair cells in the organ of Corti (Nakai
et al, 1982; Marco-Algarra et al, 1985; Ravi et al, 1995). As the
onset of ototoxic damage effects the basal cochlear windings, it can
only be detected at very high frequencies ofhearing. Ultra-high-tone
audiometry (8-20 kHz) would be favourable for the early evaluation
of ototoxicity, but is only available in specialized centres (Dreshler
et al, 1985; van der Hulst et al, 1988; Fausti et al, 1994). However,
as hearing for speech mainly involves frequencies between 0.5 and
4 kHz, conventional audiometry is an easily available, non-invasive
diagnostic method that can be used for the quantification ofhearing
impairment and long-term follow-up. In addition, our results
confirm the importance of obtaining a thorough auditory history, as
very disturbing, persisting ototoxic tinnitus sometimes fails to be
diagnosed by conventional audiometry alone.
In our cohort of patients with platin-based chemotherapy for
testicular cancer, we obtained 66% pathological audiograms, with
42% possibly related to cisplatin ototoxicity. This is in agreement
with other studies of similar cohorts showing between 28% and
77% of pathological audiograms (Bissett et al, 1990; Boyer et al,
1990; Stuart et al, 1990; Osanto et al, 1992; Schwabe et al, 1992).
After platin-based treatment for other tumour entities, ototoxic
changes have been reported in up to 91% of patients (Helson et al,
1978). This could be due to either higher doses or different modes
ofcisplatin application or due to older patient cohorts. Presbyacusis
(hearing impairment due to old age) may show a similar audio-
metric constellation as ototoxic damage (Helson et al, 1978).
Ototoxic symptoms after chemotherapy for testicular cancer
have been described in 2-37% ofpatients (Fossa et al, 1986; Stoter
et al, 1989; Aass et al, 1990; Boyer et al, 1990). A history ofsymp-
tomatic ototoxicity was given by 30% of our patients, of which
one-third reported complete reversibility. Among the 20% of
patients with persisting symptoms, 12% had tinnitus, 3% had
hearing impairment and 5% both symptoms. Otalgic symptoms
were not stated and seem to be rare (Reddel et al, 1982). The
reported frequencies of symptomatic ototoxicity in patients with
testicular cancer seem to depend on the method of investigation.
Chart review only may result in an underestimation of sympto-
matic patients (2-4%; Fossa et al, 1986; Moul et al, 1989). Some
of our interviewed patients thought of tinnitus as an unspecific
indicator of stress related to the diagnosis of cancer. Structured
interviews have shown prevalences of 15-37% (Stoter et al, 1989;
Aass et al, 1990; Boyer et al, 1990; Schwabe et al, 1992). The
observation that ototoxic symptoms do not always correlate with
the findings of conventional audiometry has been reported before
(Reddel et al, 1982; Melamed et al, 1985; Domenech et al, 1990).
There have been few reports of symptomatic vestibular dizziness,
as an expression of damage of the vestibular organ after cisplatin
exposure; yet data remain controversial (Black et al, 1982; Reddel et
al, 1982; Schaefer et al, 1985; Aass et al, 1990; Barr-Hamilton et al,
1991). None ofour patients experienced typical attacks.
The main finding of our investigation is a strong correlation
between ototoxicity and the cumulative dose of cisplatin, which is
significant in all stratified analyses and statistical tests. It has been
controversially discussed whether high single doses or high cumu-
lative doses ofcisplatin are more important for the development of
persisting ototoxicity (Nakai et al, 1982; Reddel et al, 1982;
Vermorken et al, 1983; Schaefer et al, 1985; Bissett et al, 1990;
Boyer et al, 1990; Stuart et al, 1990; Waters et al, 1991; Hallmark
et al, 1992; Saito and Aran, 1994). In our patients, audiometric
threshold deviations compatible with persisting ototoxicity were
seen in all patients with the application of high single doses of
cisplatin (35-50 mg m-2) when cumulative doses > 550 mg m-2
were reached and in all patients with cisplatin > 600 mg m-2,
regardless of the single dose given. Of the 16 patients with
> 600 mgm-2, cisplatin only five(31%) remained asymptomatic.
Vinca alkaloids have been postulated as ototoxic (Schweitzer,
1993), but this has not been confirmed in systematic clinical trials.
We could not establish a higher risk for patients receiving vinblas-
tine instead of etoposide in combination with comparable doses of
cisplatin. However, a significant increase in the prevalence of
ototoxic symptoms in patients receiving vincristine was found.
The trend for vincristine as risk factor, particularly for transient
ototoxicity, warrants further investigation in larger cohorts.
Other ototoxic agents, such as aminoglycoside antibiotics, or
loop diuretics, such as furosemide, have been held responsible for
potentiating the ototoxicity of cisplatin in experimental studies
(Reddel et al, 1982; McAlpine and Johnstone, 1990; Riggs et al,
1996). Neither our results nor other clinical studies have
confirmed an independently increased risk of ototoxicity in
patients receiving furosemide in addition to cisplatin (Vermorken
et al, 1983; Skinner et al, 1990; Hallmark et al, 1992).
A history of prechemotherapeutic sensorineural ear damage or
chronic noise exposure was associated with a significantly
increased risk (> threefold) for ototoxicity in our patients. In
particular, the correlation of symptomatic ototoxicity with a
history of noise exposure confirms similar observations by
Vermorken et al (1983), Melamed et al (1985) and van der Hulst
et al (1988). Only prospective trials can further elucidate this
association, as an overestimation might be caused by recall bias.
Interestingly, Gratton et al (1990) and Laurell (1992) have shown a
significant potentiating effect of acute noise exposure during or up
to 2 days before the application of cisplatin in animal models -
further investigations are necessary for the clinical setting, e.g.
loud music exposure by earphones during chemotherapy.
Old age as a risk factor for ototoxicity remains controversial
(Melamed et al, 1985; van der Hulst et al, 1988; Hallmark et al,
1992; Blakley et al, 1994). As patients with testicular cancer
comprise a relatively young homogeneous age group, they do not
present an adequate cohort to study this question. Our observation
that prechemotherapeutic kidney function is correlated with the inci-
dence of ototoxicity is in accordance with the reports of Schaefer
et al (1985) and Hallmark et al (1992). Other risk factors that have
been documented are aural radiotherapy (Skinner et al, 1990) and
low haemoglobin, red blood cell count and serum albumin at the
time of chemotherapy (Blakley et al, 1994). We could not confirm
the association of serum albumin and ototoxicity. Studies have
recently shown a low-protein diet with reduced serum albumin to
constitute an increased risk for ototoxicity by reducing cochlear
glutathione levels (Lautermann et al, 1995). This could be ofimpor-
tance, as the protection conferred by diethyldithiocarbamate against
cisplatin ototoxicity seems to be associated with the sparing of
cochlear glutathione (Church et al, 1995; Rybak et al, 1995).
Disturbances of electrolyte homeostasis have also been held
responsible for pharmacological ototoxicity (Dolev et al, 1983;
Gunther et al, 1988). As cisplatin nephrotoxicity can lead to salt
wasting, a pathophysiological relationship may be possible
(Schilsky, 1982). Hypophosphataemia andhypomagnesaemiarepre-
sent two major long-term sequelae ofplatin-based chemotherapy in
ourcohort oftesticular cancer patients (Bokemeyeret al, 1996), and
a trend towards an association between hypophosphataemia and
hypomagnesaemia and ototoxicity was observed.
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One clinically important, yet controversially discussed aspect is
that of the reversibility of ototoxic damage. Some of the patients
seemed to experience partial orcomplete reversibility ofthe subjec-
tive and/or objective hearing loss. Aguilar-Markulis et al (1981)
reported acomplete normalization in 2% and apartial normalization
of the audiometric abnormalities in 26% of his patients with
cisplatin-induced ototoxicity. Other studies show no audiometric
change over atime period ofup to 5 years aftercisplatin application
(Brock, 1991). Reversibility oftinnitus seems to be more common,
often accompanied by persisting threshold abnormalities (Reddel et
al, 1982; Melamed et al, 1985). In our cohort, 10% of patients
experienced transient symptoms, mostly tinnitus; only 67% of
the respective audiograms were completely normal. None of the
patients with reversible symptoms had received a cumulative dose
> 525 mg i-2 of cisplatin. On the other hand, it is important
that, among all our patients with symptomatic ototoxicity without
prechemotherapeutic hearing impairment, none had a worsening of
symptoms with increasing time offollow-up.
The association of persisting ototoxicity with other
chemotherapy-related toxicities (e.g. neurotoxicity, myelotoxicity,
nephrotoxicity) has been described (Piel et al, 1974; Vermorken et
al, 1983; Schaefer et al, 1985; Bissett et al, 1990). In our patients,
the association of ototoxicity with other long-term toxicities, such
as symptomatic neurotoxicity and gonadal toxicity, were of statis-
tical significance, implying an increased risk ofindividuals for the
manifestation ofmultiple toxicities or a common pathogenic agent,
such as the cumulative dose ofcisplatin (Bokemeyer et al, 1996).
In conclusion, cisplatin-related ototoxicity represents a
persisting symptomatic toxicity in 20% of patients after
chemotherapy for testicular cancer. The prevalence of persisting
symptoms increases to over 60% in patients with cumulative
doses of> 600 mg m-2 ofcisplatin. The symptoms experienced by
patients with lower cumulative doses of cisplatin have an almost
50% chance of complete reversibility. Vincristine may potentiate
cisplatin ototoxicity. Pre-existing hearing loss or chronic noise
exposure clearly increases the risk for persisting auditory symp-
toms at least threefold, raising the question of clinical implica-
tions. Trials focusing on the ability ofchemical substances, such as
amifostine, to protect normal tissue from cisplatin toxicity are
becoming increasingly important (Kemp et al, 1996). Future
studies should prospectively evaluate the risk factors identified
and use them as stratification criteria for clinical trials aiming at
the prevention ofcisplatin induced ototoxicity.
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